Kwality Pharmaceuticals Ltd. (KPL) is pleased to announce that it has successfully obtained product approval in South Africa (SAHPRA) for our prominent oncology oral solid dosage (OSD) product, Tamoxifen 20mg Tablet, through a site transfer process.

This approval is a significant achievement in expanding the availability of this critical therapeutic, which plays a vital role in the treatment of hormone receptor-positive breast cancer. It reflects our ongoing commitment to providing high-quality, accessible oncology treatments to patients in key markets.

This approval further strengthens our presence in the High Regulated and global oncology market.